Serena Nik Zainal discusses the key themes of this year’s plenary lectures and new developments in the field.
1. What were the key themes of this year’s plenary lecture “Advances in the Understanding of Mutational Signatures in Human Cells”? (00:04)
2. What have been the key developments in your area of research over the past year? (01:01)
3. What new areas of research do you expect to emerge in 2018? (01:46)
4. Which sessions have interested you most at this year’s SABCS? (02:39)
Speaker disclosures: Serena Nik-Zainal has nothing to disclose in relation to this video interview.
Filmed at the San Antonio Breast Cancer Symposium (SABCS), 40 Year Anniversary, San Antonio, Texas, USA, December 2017.
Related Videos In Breast Cancer
Priyanka Sharma, ASCO20: New Combination Therapy in the Treatment of Triple-Negative Breast Cancer
Priyanka Sharma, University of Kansas, joins us to discuss the data from the SWOG S1416 study (Clinicaltrials.gov identifier: NCT02595905) presented at the ASCO20 Virtual Scientific Programe on the combined use of PARP inhibitors and chemotherapy in the treatment of triple-negative breast cancer. Questions 1. What are the major unmet needs in the treatment of triple-negative […]
Anna van der Voort, ASCO20: Three-year Follow-up of the TRAIN-2 Phase III Trial
We were delighted to speak to Dr Anna van der Voort, The Netherlands Cancer Institute, to discuss her presentation at the ASCO20 Virtual Scientific Program on the long-term follow-up data of the randomised, multicentre, open-label phase III TRAIN-2 trial (ClinicalTrials.gov Identifier: NCT01996267). Questions 1. What are the major unmet needs in current neoadjuvant chemotherapy regimes […]
Javier Cortes, ASCO20: Key findings of the KEYNOTE-355 study
touchONCOLOGY were delighted to speak to Javier Cortes to discuss the key findings of the KEYNOTE-355 study, a randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Questions 1. What are the challenges in the treatment of triple-negative breast cancer? (0:06) 2. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!